By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expedeon and Protein Discovery today announced that they have signed a merger agreement.

Under the terms of the deal, the new company will keep the Expedeon name and remain headquartered in Cambridge, UK. Heikki Lanckriet, founder and CEO of Expedeon, will be the CEO of the new firm. Chuck Witkowski, founder and CEO of Protein Discovery, will join Expedeon's board of directors, the firms said.

Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.